Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The hypercoagulable state of malignancy: pathogenesis and current debate.

Graham J Caine1, Paul S Stonelake, Gregory Y H Lip

  • 1Hemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham B18 7QH, UK. graham.caine@cityhospbham.wmids.nhs.uk

Neoplasia (New York, N.Y.)
|October 31, 2002
PubMed
Summary

Cancer malignancy causes a hypercoagulable state, increasing mortality. Understanding cancer-associated thrombosis mechanisms may lead to targeted treatments and improved patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acute management of atrial fibrillation.

Chest·2009
Same author

Efficacy and safety of drug-eluting stent use in patients with atrial fibrillation.

European heart journal·2009
Same author

Illness perceptions, affective response, and health-related quality of life in patients with atrial fibrillation.

Journal of psychosomatic research·2009
Same author

Monocytes in acute coronary syndromes.

Arteriosclerosis, thrombosis, and vascular biology·2009
Same author

Generalized obesity but not that characterized by raised waist-hip ratio is associated with increased perceived breathlessness during treadmill exercise testing.

Cardiovascular therapeutics·2009
Same author

Plasma indices of angiogenesis in rheumatoid disease: relationship to cardiovascular risk factors and cardiac function.

International journal of cardiology·2009

Area of Science:

  • Oncology
  • Hematology
  • Pathophysiology

Background:

  • Malignancy-associated hypercoagulable state significantly contributes to cancer patient mortality and morbidity.
  • Tumor cells activate coagulation via secreted factors, cell interactions, inflammation, and metabolic changes.
  • Anticancer therapies can also elevate thromboembolic event risk.

Purpose of the Study:

  • To review the pathophysiology of cancer-associated hypercoagulable states.
  • To discuss screening for malignancy in idiopathic deep venous thrombosis.
  • To explore potential benefits of antithrombotic strategies in cancer treatment.

Main Methods:

  • Literature review of current understanding of cancer-associated hypercoagulability.
  • Discussion of diagnostic and therapeutic implications.

Related Experiment Videos

Main Results:

  • Cancer cells actively promote thrombosis through various direct and indirect mechanisms.
  • Anticancer treatments can exacerbate prothrombotic tendencies.
  • The precise mechanisms underlying cancer hypercoagulability are not fully elucidated.

Conclusions:

  • Further research into cancer-associated thrombosis is crucial for developing targeted preventive strategies.
  • Antithrombotic therapies may offer dual benefits for cancer treatment and complication prevention.
  • Screening for malignancy in deep venous thrombosis patients warrants further investigation.